Abstract Background: Neuregulin (NRG)-1-human epidermal receptor (HER)-2 signaling pathway is a key regulator of IL-1β-mediated pulmonary inflammation and epithelial permeability. The inflammasome is a newly discovered molecular platform required for caspase-1 activation and maturation of IL-1β. However, the role of the inflammasome in NRG-1-HER2 signalingmediated alveolar cell permeability is unknown. Methods: The inflammasome was activated or inhibited in THP-1 cells; supernatants from these cells were added to A549 cells and human small airway epithelial cells (HSAEC). The protein expression of NRG-1 and phospho-HER2 (pHER2) were measured by Western blot analysis and epithelial permeability was measured using Lucifer yellow dye. Results: Results reveal that alveolar permeability in A549 cells and HSAEC is increased when treated with supernatants of inflammasome-activated THP-1 cells. Alveolar permeability is significantly suppressed when treated with supernatant of inflammasome-inhibited THP-1 cells. Inflammasome-mediated permeability is decreased when A549 cells and HSAEC are pretreated with IL-1β receptor antagonist (IL-1βRA). In addition, HER2 kinase inhibitor AG825 or NRG-1 inhibitor TAPI inhibits inflammasomemediated permeability in A549 cells and HSAEC demonstrating critical roles of IL-1β, NRG-1, and HER2 in inflammasome-mediated alveolar permeability. Conclusion: These findings suggest that inflammasome-induced alveolar cell permeability is mediated by NRG-1/HER2 signaling through IL-1β regulation.
Treatment with inflammasome stimulators or inhibitors
THP-1 cells were differentiated by adding 0.5 µg/ml of PMA to the medium for 3 hours, then the medium was replaced with RPMI plus 0.1% serum overnight. After 24 hours, cells were briefly washed with PBS. Then, 0.5 µg/ml of nigericin or 0.25 mM ATP, in the presence or absence of 1.25 µg/ml glyburide or 130 mM KCl, was added to the medium for 1 hour. The activation of the inflammasome was confirmed by measuring the IL-1β secretion, and the supernatant was added to 80% confluent epithelial or endothelial cells for up to 5% of the mentioned time.
Cell Permeability Measurement
The permeability was assessed in HSAEC and A549 monolayers on a BD Falcon 96-multiwell insert platform (BD Biosciences, Bedford, MD, USA) using measured passage of Lucifer yellow dye (Sigma-Aldrich). Monolayers in the hanging insert were incubated with the required concentration of THP-1-conditioned supernatants or IL-1β with or without mentioned inhibitors for 24 hours. PMA-conditioned medium in the absence of other additives was used as control cells. To analyze permeability, Lucifer yellow dye (100 µg/ ml) in HBSS was added to the monolayer in the top well, and the bottom well was filled with 270 µl HBSS. After 1-4 hours, fluorescence in the bottom well was measured by spectrophotometer at excitation 485 nm and emission 510 nm [21, 27] . The permeability coefficient was calculated as directed by the 96-multiwell insert platform supplier (BD Biosciences).
Western blot
Cells were lysed with RIPA buffer and protein concentration was determined by using the BCA assay kit. Uniform quantity of protein, as assessed by BCA assay, was run on SDS-PAGE, and protein was transferred to the PVDF membrane by following the previously mentioned method [32] . The membrane was blocked for 1 hour in PBS/T (PBS containing 0.05% TWEEN 20) containing 5% nonfat dry milk. Primary and secondary antibodies were diluted to 1000-fold in PBS/T with 2.5% nonfat milk. Probing with antibodies and washing steps were followed as previously mentioned [32] . Protein levels were detected using a Pierce ECL Western blotting substrate kit (Thermo scientific Rockford, IL, USA) according to the manufacturer's instructions and exposed in a ChemiDoc XRS (Biorad, Hercules, CA, USA). The intensity of bands were measured and normalized to GAPDH.
Measurement of IL-1β and NRG-1 secretion
Human IL-1β ELISA Ready-SET-Go kit (eBioscience, San Diego, CA, USA) was used to quantify the IL-1β levels in the THP-1 cell culture supernatant according to the manufacturer instructions [21] . The secretion of NRG-1 was measured by using Duoset human NRG1-β1 kit according to the manufacturer instructions with minor modifications (R&D technologies, Minneapolis, MN, USA) [33] .
Statistics
Data was statistically analyzed by GraphPad Prism version 10.00 for Windows (GraphPad Software, San Diego, CA). Comparison of continuous variables between two groups was performed using Student's t-test. All tests were two-tailed and results were considered significant at p < 0.05. Venugopal et 
Results

Inflammasome activators increases IL-1β secretion in THP-1 supernatants
In the initial experiments, we sought to determine if inflammasome activators can induce IL-1β processing and secretion in THP-1 cells. For this current study, THP-1 cells were selected because of their similarity to the activated alveolar macrophages present in bronchoalveolar lavage (BAL) fluid [21] . In addition, differentiated THP-1 cells have a unique characteristic feature of processing and secretion of IL-1β mediated by inflammasome activation. THP-1 cells were initially differentiated using 0.5 µg/ml of PMA. Differentiated THP-1 cells were treated with either 0.5 µg/ml of nigericin or 0.25 mM ATP to induce inflammasome activation. The levels of mature IL-1β (end product of the inflammasome) in THP-1 supernatants by ELISA were measured. Results revealed that inflammasome activators nigericin and ATP increase the levels of IL-1β in supernatants but, inflammasome inhibitor glyburide suppresses nigericin-or ATP-induced (inflammasome-mediated) IL-1β processing and secretion (Fig. 1A) . Western blot analysis probed for mature IL-1β from the inflammasome activators nigericin and ATP treatments showed similar results consistent with ELISA (Fig. 1B) . These results indicate that nigericin and ATP induce inflammasome complex formation thereby increasing the inflammasome-mediated IL-1β secretion in THP-1 culture supernatants. Supernatants from these THP-1 cells (inflammasome induced and/ or suppressed) were referred as conditioned supernatants, and were used to assess the functional effects of the inflammasome in further experiments.
Activation of the inflammasome increases alveolar epithelial permeability in HSAEC
Activated alveolar macrophages release inflammatory cytokines which leads to an increase in epithelial permeability and cell injury that ultimately causes cell death in ALI. However, the functional effects of inflammasome activation on epithelial permeability are not clearly defined. To determine this, THP-1 cells were treated with inflammasome activators and/or inhibitors; then the conditioned supernatants were added to primary HSAEC. After 24 hours, permeability was measured by calculating the penetration of Lucifer yellow dye. Our data showed an increase in epithelial permeability in HSAEC when treated with inflammasome-activated supernatants from THP-1 cells. However, supernatants from THP-1 cells treated with inflammasome inhibitors like glyburide or KCl decrease the permeability ( Fig. 2A-2D) . To avoid the possible additional cytotoxic effects of nigericin, ATP, glyburide, or H 2 O 2 in THP-1 supernatants, HSAEC were treated with concentrations ranging from 0.125 to 1 µg/ml of nigericin, 0.3125 to 2.5 µg/ml of glyburide, and 0.0625 to 0.5 mM of ATP or H 2 O 2 , and cytotoxicity was determined by MTT assay (Fig. 3A-3D ). The concentrations of 0.5 µg/ml of nigericin, 1.25 µg/ml of glyburide, 0.25 mM of ATP, or H 2 O 2 transferred along with the 5% of THP-1 culture supernatants did not affect the cell viability in HSAEC. These results suggest that inflammasome activation induces alveolar macrophage-mediated production of IL-1β which causes a significant increase in alveolar epithelial permeability.
Inflammasome inhibitors increases the retention of NRG-1 in HSAEC
Studies suggest that NRG-1 shedding induces alveolar epithelial permeability leading to epithelial barrier dysfunction thereby causing ALI. Based on the observations that inflammasome activation increases alveolar epithelial permeability, it was hypothesized that inflammasome activation and increased alveolar permeability is mediated through shedding of NRG-1. To investigate this mechanism, supernatants from inflammasome-induced and/ or suppressed THP-1 cells were added to HSAEC. In another set of experiments, THP-1 cells were exposed to recombinant human IL-1β or nigericin in the presence or absence of glyburide or IL-1βRA; the supernatants were added to HSAEC. NRG-1 retention content from whole cell lysates from all of the experiments mentioned above was analyzed by Western blot. The addition of nigericin-or ATP-treated conditioned medium to HSAEC decreased the retention levels of NRG-1 when compared to untreated supernatants as indicated by the intracellular protein content. Also, inflammasome inhibition by glyburide increased the retention of NRG-1 in whole cell HSAEC lysates (Fig. 4A-4B ). Since IL-1β is the end product of the inflammasome, we tested whether IL-1β can modulate NRG-1 shedding by exposing HSAEC to recombinant human IL-1β. Results indicate that IL-1β induced NRG-1 shedding Venugopal Fig. 5A -5B). The pretreatment of IL-1βRA prevented the nigericin-, IL-1β-, or ATP-mediated decrease in NRG-1 in whole cell lysates (Fig. 5B) . These results suggest that inflammasome suppression increases the retention of NRG-1 in HSAEC.
Inflammasome activation increases the NRG-1 release NRG-1 shedding and HER2 activation participate in epithelial barrier dysfunction in ALI, additionally, elevated NRG-1 levels have been detected in blood samples from patients with ALI [27] . NRG-1 content was analyzed by ELISA to confirm whether reduced retention of NRG-1 by the inflammasome is due to the shedding and secretion of NRG-1 into supernatant. Subsequently, THP-1 cells were activated and/or inhibited using ATP or nigericin in the presence or absence of glyburide or KCl, and the supernatants from these treatments were added to HSAEC and A549 cells. The amount of NRG-1 in the supernatants was measured by ELISA. In HSAEC and A549 cells, supernatants collected from THP-1 treatments with nigericin or IL-1β increased NRG-1 secretion, whereas glyburide and IL-1βRA prevented this effect (Fig. 6A-6B ). These results confirm that inflammasome activation increases the shedding of NRG-1 and lowered the retention levels of NRG-1 in HSAEC and A549 cells.
The inflammasome activates HER2
NRG-1 is a known ligand for HER2 signaling [28] . The shedding of NRG-1, subsequent HER2 activation, and initiation of downstream signaling result in the loss of alveolar and airway epithelial barrier function and pulmonary edema [27, 34] . These findings indicate that inflammasome activation induces NRG-1 shedding, confirming the downstream effects of the inflammasome on NRG-1 shedding-mediated activation of HER2. The expression of [A] THP-1 cells were treated with nigericin and ATP in the presence or absence of glyburide and the conditioned supernatants were added to HSAEC for 1 hour. In addition, IL-1β (10 ng/ml) was directly added to HSAEC to study the effect of IL-1β. NRG-1 in 50 µg of total cell lysates was studied by immunoblot (top) and intensity ratio of NRG1/GAPDH was obtained (bottom).
[B] To inhibit the IL-1β signaling, IL-1βRA was added 1 hour prior to the addition of conditioned media and NRG-1 expression was studied by immunoblot (top) and intensity ratio of NRG1/GAPDH (bottom). The noted experiments are representative of a minimum of three similar evaluations. pHER2 in whole cell lysates was detected by Western blot analysis. Supernatants from THP-1 cells treated with nigericin or ATP in the presence or absence of glyburide were added to A549 cells. At 1, 2, 4, and 6 hour post-addition, the expression of pHER2 in whole cell lysates of A549 was checked by Western blot analysis. Inflammasome activators (nigericin and ATP) increased the expression of pHER2, whereas the presence of glyburide decreased the expression levels (Fig. 7) . This shows that activation of the inflammasome increases the shedding of NRG-1 into the supernatants and results in the activation of HER2.
Activation of HER2 by the inflammasome is IL-1β dependent
Supernatants from THP-1 cells treated with nigericin or ATP in the presence or absence of glyburide were added to A549 cells to investigate the involvement of IL-1β in inflammasome- showed that the presence of IL-1βRA prevented the induction of pHER2 demonstrating that the inflammasome-mediated regulation is IL-1β dependent (Fig. 8 ). In addition, the effect of pHER2 activation inhibitor molecule and NRG-1 shedding blockade molecule on nigericinmediated activation of HER2 was investigated. Results suggest that TAPI-2 and AG-825 prevent nigericin-mediated activation of HER2.
The inflammasome effect on cell permeability is IL-1β dependent
Based on the observations above, it was hypothesized that inflammasome-mediated cell permeability is IL-1β dependent. IL-1β (10 ng/ml) was directly added to HSAEC and cell permeability was analyzed to investigate whether inflammasome-mediated permeability occurs through IL-1β. Results indicate that the addition of glyburide or KCl did not prevent the effect of IL-1β-induced permeability (Fig. 9) . A549 cells were also pretreated with or without IL-1βRA one hour prior to the addition of THP-1 supernatant treated with activators and/or inhibitors of the inflammasome. Our results showed that nigericin-or ATP-treated 8 . Activation of pHER2 is IL-1β dependent. HSAEC were treated with conditioned media from THP-1 cells exposed with nigericin and ATP for 1 hour. Recombinant IL-1β (I) was directly added to HSAEC. IL-1βRA, TAPI, or AG825 molecules were added 1 hour prior to the addition of the conditioned supernatants to block the NRG-1 and HER2 signaling. The expression of pHER2, HER2, and GAPDH in 50 µg of total cell lysates was checked by immunoblot analysis. The noted experiments are representative of a minimum of three similar evaluations.
Permeability Coefficient X 10 -6 + IL-1βRA -IL-1βRA Fig. 9 . Inflammasome-mediated increase in cell permeability is IL-1β dependent. A549 cells were pretreated with THP-1-conditioned supernatants exposed to nigericin, ATP, glyburide, and KCl for 24 hours. IL-1βRA was added 1 hour before treatment. The relative permeability assessed by using a Lucifer yellow dye based assay. HSAEC treated with glyburide or KCl exposed THP-1-conditioned supernatants along with IL-1β and permeability was calculated. supernatants increased the permeability, and the co-treatment of glyburide decreased the nigericin effect (Fig. 9) . A decrease in nigericin-or ATP-mediated induction of permeability was observed in the IL-1βRA pretreated condition (Fig. 9) . These results suggest that inflammasome-mediated cell permeability is IL-1β dependent.
Discussion
The majority of investigations on the inflammasome have been largely restricted to immune cells, so studying the influence of innate immune cells such as activated monocytes in alveolar epithelial dysfunction may provide a source for rapid integration of basic and clinical data for translational research [35] . Recent studies suggest novel contributors that may regulate activation of the inflammasome [36, 37] . In addition, studies also demonstrate that underlying pathophysiologic factors in ALI such as alveolar epithelial barrier permeability and increased IL-1β levels are diminished [37] . The presented data links the functional effects of inflammasome activation on resident epithelial cells. The novel role of the inflammasome is discovered in NRG-1 shedding which results in downstream HER2 signaling and leads to an increase in alveolar epithelial permeability. NRG-1 levels are elevated in pulmonary edema fluid from patients with ALI receiving mechanical ventilation. Since this pathway induces NRG-1 retention, it may prove to be a worthy therapeutic approach to ALI. Blocking NRG-1 shedding will ultimately inhibit epithelial barrier dysfunction, the key event in ALI (Fig. 10) . In our previous work, we observed that activation of the inflammasome leads to increased alveolar permeability in ALI [21] . The questions of whether inflammasome activation induces NRG-1 shedding, HER2 activation, and alveolar permeability elevation, a hallmark of ALI, are unknown. In this study, the inflammasome regulates paracrine activation of epithelial cell permeability. The implications of the proinflammatory cytokine IL-1β in lung injury is known in both in vitro and in vivo models [38] [39] [40] [41] [42] . Involvement of mature IL-1β in the disruption of epithelial cell permeability and modulation of NRG-1 and HER2 signaling has important implications in ALI and other pulmonary diseases [27] . However, the upstream mechanisms that initiate IL-1β-mediated NRG-1 shedding and signaling of HER2 remain unknown.
In this report, the inflammasome was stimulated in THP-1 monocytes and supernatants from these cells were used to treat HSAEC and A549 cells. Low amounts of inflammasome The shedding of neuregulin is evidenced by decreased retention of NRG-1 in cell lysates and increased NRG-1 in supernatants of epithelial and endothelial cells when treated with supernatants from inflammasome-stimulated THP-1 cells. Similar to this model, ex vivo bone marrow macrophage supernatant-conditioned medium was used to study the inflammasome-mediated, insulin-induced Akt phosphorylation in a previous report [43] .
Investigations also demonstrate that NRG-1 is released into extracellular space by ADAM-17 sheddase molecule, and IL-1β downstream signaling further enhances the sheddase function of ADAM-17. Specific pharmacological inhibitor of ADAM-17 decreases HER2 activation in IL-1β-stimulated epithelial cells consistent with previous studies with TAPI-2 in IL-1β-stimulated epithelial cells [27] . Recent findings confirm that the ADAM17-NRG-1-HER2 pathway contributes in the pathophysiology of ALI [44] . In addition to these findings, the present study shows that the functional effects of the inflammasome on cell permeability are an IL-1β-dependent process. IL-1βRA decreases inflammasome-mediated induction of permeability, showing that additional factors other than IL-1β signaling may be involved in epithelial permeability and therefore further studies may be necessary. ALI is a heterogeneously diffused respiratory disorder that affects approximately 200,000 patients yearly in the United States [1] and no therapies are currently available to cure this disorder. This study demonstrates a way to regulate IL-1β-associated disorders such as ALI through the modulation of the inflammasome. Regulating the inflammasome will help control cell permeability and in turn severity of ALI at an early stage by blocking the downstream IL-1β-mediated NRG-1 and pHER2 signaling. Hence, in a clinical perspective, targeting the inflammasome the may be a novel therapeutic approach to suppress ALI and protect against other inflammasome-mediated inflammatory diseases.
